Canntab Discusses Hemp Supply Agreement with FSD Pharma and Canada’s Second Wave of Cannabis Legalization

Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1) CFO Richard Goldstein was featured in an interview on Midas Letter.

Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and...

Canntab Provides Corporate Update

Canntab Therapeutics (CSE:PILL) (OTC:CTABF, FSE:TBF1) (“Canntab” or the “Company”) is pleased to provide an update on a number of significant...

Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

Canntab Therapeutics (CSE:PILL) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it...

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.

Emblem CEO: Product Innovation, Brand Building and Distribution in Cannabis

Emblem CEO Nick Dean addresses the company’s shift to product innovation, brand development and distribution in the cannabis industry.

Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

Canntab Therapeutics (CSE:PILL) (“Canntab” or the “Company”), today announces the launch of a research partnership with world-renowned orthopaedic surgeon, Dr....